Drug intelligence / Profile preview

JWATM213

Development stage: Unknown
Lead developer: JW Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

JWATM213 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting alpha-fetoprotein (AFP), developed by Shanghai Ming Ju Biotechnology, a subsidiary of JW Therapeutics. Currently in Phase 1 clinical development, it is designed for the treatment of hepatocellular carcinoma (HCC). The therapy utilizes T cells engineered to recognize AFP-derived peptides presented by HLA-A*02:01 on the surface of tumor cells. By targeting AFP, a protein frequently overexpressed in HCC, JWATM213 aims to provide a precision immunotherapy option for patients with advanced liver cancer who have limited treatment alternatives.

Targets

Alpha-fetoprotein-derived peptide presented by Human Leukocyte Antigen class I

Beyond the preview

Go deeper on JWATM213.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JWATM213.

Explore the full profile